HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MRPS22
mitochondrial ribosomal protein S22
Chromosome 3 Β· 3q23
NCBI Gene: 56945Ensembl: ENSG00000175110.14HGNC: HGNC:14508UniProt: A0A7P0MKV3
169PubMed Papers
22Diseases
0Drugs
19Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
mitochondrionprotein bindingstructural constituent of ribosomemitochondrial small ribosomal subunithypotonia with lactic acidemia and hyperammonemia46,XX gonadal dysgenesisneurodegenerative disease46 XX gonadal dysgenesis
✦AI Summary

MRPS22 encodes a structural component of the mitochondrial small ribosomal subunit, essential for mitochondrial translation and protein synthesis 1. As a nuclear-encoded mitochondrial ribosomal protein, MRPS22 is critical for oxidative phosphorylation system biogenesis and ATP production 2. During development, MRPS22 is required to initiate gastrulation, with loss resulting in severe developmental delay and failure to progress past the egg-cylinder stage due to compromised mitochondrial function 3. MRPS22 mutations cause two distinct phenotypic spectra. Biallelic missense mutations (p.R135Q, p.R202H) cause primary ovarian insufficiency (POI) in adolescent females through a germ cell-autonomous mechanism, where mitochondrial defects appear tissue-specific rather than affecting overall bioenergetic capacity 4. Conversely, other MRPS22 mutations cause severe mitochondrial disease presenting in infancy with developmental delay, hypotonia, and distinctive brainstem/thalamic lesions 5. Recently, adult-onset neurological disorders associated with MRPS22 mutations have been characterized by leukoencephalopathy, cerebellar ataxia, motor neuropathy, and profound cerebral folate deficiency, responding to folinic acid supplementation 2. MRPS22 mutations account for approximately 10-20% of genetic POI cases and represent a rare but important cause of combined oxidative phosphorylation deficiency 6. Therapeutic approaches remain personalized and mutation-specific 7.

Sources cited
1
MRPS22 functions in mitochondrial translation and is associated with POI through mitochondrial dysfunction
PMID: 31393557
2
MRPS22 bi-allelic variants cause adult-onset leukoencephalopathy with cerebral folate deficiency and impaired mitochondrial translation
PMID: 41506652
3
Mrps22 knockout in mouse embryos results in failure to initiate gastrulation and reduced ATP production
PMID: 32376682
4
MRPS22 homozygous missense mutations cause POI through germ cell-autonomous mechanisms independent of systemic bioenergetic defects
PMID: 29566152
5
MRPS22 splicing mutations cause severe infantile mitochondrial disorder with developmental delay and brainstem lesions
PMID: 28752220
6
MRPS22 is among genes associated with metabolic dysfunction-related POI etiology
PMID: 34794894
7
MRPS22 mutations cause combined respiratory complex deficiency; therapeutic responses are patient-specific
PMID: 24012549
Disease Associationsβ“˜22
hypotonia with lactic acidemia and hyperammonemiaOpen Targets
0.79Strong
46,XX gonadal dysgenesisOpen Targets
0.65Moderate
neurodegenerative diseaseOpen Targets
0.52Moderate
46 XX gonadal dysgenesisOpen Targets
0.52Moderate
androgenetic alopeciaOpen Targets
0.48Moderate
genetic disorderOpen Targets
0.47Moderate
combined oxidative phosphorylation deficiencyOpen Targets
0.41Moderate
mitochondrial diseaseOpen Targets
0.41Moderate
lobe attachmentOpen Targets
0.38Weak
Abnormality of skin pigmentationOpen Targets
0.38Weak
alopeciaOpen Targets
0.37Weak
outer ear morphology traitOpen Targets
0.31Weak
lobe sizeOpen Targets
0.31Weak
Attached earlobeOpen Targets
0.30Weak
pneumothoraxOpen Targets
0.26Weak
knee fractureOpen Targets
0.25Weak
pleural empyemaOpen Targets
0.24Weak
facial morphologyOpen Targets
0.16Weak
KeloidOpen Targets
0.16Weak
brain cancerOpen Targets
0.15Weak
Combined oxidative phosphorylation deficiency 5UniProt
Ovarian dysgenesis 7UniProt
Pathogenic Variants19
NM_020191.4(MRPS22):c.878+1G>TPathogenic
not provided|Hypotonia with lactic acidemia and hyperammonemia|46 XX gonadal dysgenesis
β˜…β˜…β˜†β˜†2025
NM_020191.4(MRPS22):c.373C>T (p.Arg125Ter)Pathogenic
Inborn genetic diseases|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 125
NM_020191.4(MRPS22):c.509G>A (p.Arg170His)Pathogenic
Hypotonia with lactic acidemia and hyperammonemia|not provided|Hypotonia with lactic acidemia and hyperammonemia;Ovarian dysgenesis 7
β˜…β˜…β˜†β˜†2024β†’ Residue 170
NM_020191.4(MRPS22):c.948_949del (p.Ala317fs)Pathogenic
Hypotonia with lactic acidemia and hyperammonemia
β˜…β˜†β˜†β˜†2025β†’ Residue 317
NM_020191.4(MRPS22):c.760_763del (p.Asp254fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 254
NM_020191.4(MRPS22):c.571C>T (p.Arg191Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 191
NM_020191.4(MRPS22):c.403C>T (p.Arg135Ter)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 135
NM_020191.4(MRPS22):c.649-2A>GLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2023
NM_020191.4(MRPS22):c.544del (p.Arg182fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 182
NM_020191.4(MRPS22):c.33G>A (p.Trp11Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 11
NM_020191.4(MRPS22):c.40_41insA (p.Leu14fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 14
NM_020191.4(MRPS22):c.992_993del (p.Phe331fs)Likely pathogenic
Hypotonia with lactic acidemia and hyperammonemia
β˜…β˜†β˜†β˜†2021β†’ Residue 331
NM_020191.4(MRPS22):c.481dup (p.Ile161fs)Likely pathogenic
Hypotonia with lactic acidemia and hyperammonemia
β˜…β˜†β˜†β˜†2019β†’ Residue 161
NM_020191.4(MRPS22):c.938C>A (p.Ser313Ter)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2019β†’ Residue 313
NM_020191.4(MRPS22):c.874_875del (p.Asp292fs)Pathogenic
Hypotonia with lactic acidemia and hyperammonemia
β˜…β˜†β˜†β˜†2018β†’ Residue 292
NM_020191.4(MRPS22):c.489T>G (p.Tyr163Ter)Pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2017β†’ Residue 163
NM_020191.4(MRPS22):c.768_769del (p.Gly257fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2014β†’ Residue 257
NM_020191.4(MRPS22):c.648+1G>TPathogenic
Hypotonia with lactic acidemia and hyperammonemia
β˜†β˜†β˜†β˜†2024
NM_020191.4(MRPS22):c.644T>C (p.Leu215Pro)Pathogenic
Hypotonia with lactic acidemia and hyperammonemia
β˜†β˜†β˜†β˜†2011β†’ Residue 215
View on ClinVar β†—
Related Genes
MRPL53Shared pathway100%GADD45GIP1Shared pathway100%MRPL57Shared pathway100%MRPL38Shared pathway100%MRPS6Protein interaction100%MRPS9Protein interaction100%
Tissue Expression6 tissues
Heart
100%
Bone Marrow
86%
Liver
67%
Brain
55%
Ovary
41%
Lung
37%
Gene Interaction Network
Click a node to explore
MRPS22MRPL53GADD45GIP1MRPL57MRPL38MRPS6MRPS9
PROTEIN STRUCTURE
Preparing viewer…
PDB7QI4 Β· 2.21 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.93LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.68 [0.50–0.93]
RankingsWhere MRPS22 stands among ~20K protein-coding genes
  • #2,626of 20,598
    Most Researched169 Β· top quartile
  • #2,224of 5,498
    Most Pathogenic Variants19
  • #8,543of 17,882
    Most Constrained (LOEUF)0.93
Genes detectedMRPS22
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Genetics of ovarian insufficiency and defects of folliculogenesis.
PMID: 34794894
Best Pract Res Clin Endocrinol Metab Β· 2022
1.00
2
Mitochondrial Dysfunction in Primary Ovarian Insufficiency.
PMID: 31393557
Endocrinology Β· 2019
0.90
3
Genetics of Primary Ovarian Insufficiency in the Next-Generation Sequencing Era.
PMID: 32099950
J Endocr Soc Β· 2020
0.88
4
Genetic insights into the complexity of premature ovarian insufficiency.
PMID: 39095891
Reprod Biol Endocrinol Β· 2024
0.80
5
Mutations in the mitochondrial ribosomal protein MRPS22 lead to primary ovarian insufficiency.
PMID: 29566152
Hum Mol Genet Β· 2018
0.70